Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition

The use of adjuvant aromatase inhibitors is associated with an increased risk of osteoporosis and fractures. The oral bisphosphonate, risedronate - dosed as the US Food and Drug Administration approved for the treatment or prevention of postmenopausal osteoporosis - appears to mitigate bone loss ass...

Descripción completa

Detalles Bibliográficos
Autor principal: Van Poznak, Catherine
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917025/
https://www.ncbi.nlm.nih.gov/pubmed/20584345
http://dx.doi.org/10.1186/bcr2584
_version_ 1782185042487803904
author Van Poznak, Catherine
author_facet Van Poznak, Catherine
author_sort Van Poznak, Catherine
collection PubMed
description The use of adjuvant aromatase inhibitors is associated with an increased risk of osteoporosis and fractures. The oral bisphosphonate, risedronate - dosed as the US Food and Drug Administration approved for the treatment or prevention of postmenopausal osteoporosis - appears to mitigate bone loss associated with 2 years of adjuvant anastrozole in women with early-stage breast cancer.
format Text
id pubmed-2917025
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29170252010-12-18 Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition Van Poznak, Catherine Breast Cancer Res Editorial The use of adjuvant aromatase inhibitors is associated with an increased risk of osteoporosis and fractures. The oral bisphosphonate, risedronate - dosed as the US Food and Drug Administration approved for the treatment or prevention of postmenopausal osteoporosis - appears to mitigate bone loss associated with 2 years of adjuvant anastrozole in women with early-stage breast cancer. BioMed Central 2010 2010-06-18 /pmc/articles/PMC2917025/ /pubmed/20584345 http://dx.doi.org/10.1186/bcr2584 Text en Copyright ©2010 BioMed Central Ltd
spellingShingle Editorial
Van Poznak, Catherine
Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
title Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
title_full Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
title_fullStr Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
title_full_unstemmed Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
title_short Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
title_sort managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917025/
https://www.ncbi.nlm.nih.gov/pubmed/20584345
http://dx.doi.org/10.1186/bcr2584
work_keys_str_mv AT vanpoznakcatherine managingbonemineraldensitywithoralbisphosphonatetherapyinwomenwithbreastcancerreceivingadjuvantaromataseinhibition

Ejemplares similares